Bright Minds Moves Into Clinical Development Stage Following Positive Toxicity Results

Drug development continues for the Bright Minds Biosciences (CSE: DRUG) lead product. The firm this morning published positive results from a recent 28-day toxicity study conducted on its novel formulation, BMB-101, which is currently being designed for the treatment of Dravet Syndrome.

Conducted by the firms contract research partner ITR Laboratories Canada, the study consisted of a 28-day process. The process saw twice daily oral administrations of the compound in both mice and dogs in compliance with Good Laboratory Practices.

Within the study, doses of up to 40 and 30 milligrams per kilogram per day in mice and dogs, respectively, were said to be well tolerated at all dose levels. At these levels there is said to have been no major toxic effects after a 28 day period, which includes a lack of any effect on target organs.

The data collected from the 28 day study will now be utilized in establishing safety criteria for determining the starter dose levels in human subjects.

“We are delighted to have completed this important milestone, which is pivotal for supporting our forthcoming first-in-human clinical trial, currently expected to begin in 2Q22. We have now officially entered the clinical development stage for our lead product, BMB-101, which represents an exciting new chapter for the Company and, hopefully, therapeutic alternative for patients suffering from Dravet Syndrome.”

Bright Minds Biosciences last traded at $2.01 on the CSE.


FULL DISCLOSURE: Bright Minds Biosciences is a client of Canacom Group, the parent company of The Deep Dive. The company has been compensated to cover Bright Minds Biosciences on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. We may buy or sell securities in the company at any time. Always do additional research and consult a professional before purchasing a security.

Video Articles

When 4% of Global Copper Disappears Overnight | David Gower – Emerita Resources

Mining M&A: Gold X2 Acquires Kesselrun Resources

They Said Oil Was Dead. They Were Wrong. | Michael Judson – Record Resources

Recommended

Military Seizes Power in Madagascar After President Flees

Altamira Gold Hits 395.5 Metres Of 0.4 g/t Gold At Maria Bonita

Related News

Bright Minds: Eight Capital Assigns $11.50 Price Target To Firm

Last week, Eight Capital launched coverage on a basket of psychedelic companies. This comes after...

Monday, September 20, 2021, 10:09:00 AM

Psychedelics: The Eight Capital Primer

Eight Capital recently produced a primer on the psychedelic sector saying that the companies are...

Monday, June 14, 2021, 03:38:00 PM

Bright Minds Bioscience: A Deep Dive

Today we are diving into a firm focused on mental health, whom is also a...

Thursday, December 2, 2021, 01:30:00 PM

Bright Minds Begins Phase 1 Clinical Trials Focused On Treating Dravet Syndrome

Phase 1 trials are officially underway for Bright Minds Biosciences (CSE: DRUG) and their lead...

Wednesday, August 31, 2022, 08:52:31 AM

Bright Minds Biosciences: Corporate Overview

Bright Minds Biosciences Inc. (CSE: DRUG) is a small-cap preclinical biosciences company that is attempting to...

Monday, May 31, 2021, 02:43:00 PM